SARS-CoV-2-Mimicking Pseudoviral Particles Accelerate α-Synuclein Aggregation In Vitro
Since the SARS-CoV-2 virus started spreading worldwide, evidence pointed toward an impact of the infection on the nervous system. COVID-19 patients present neurological manifestations and have an increased risk of developing brain-related symptoms in the long term. In fact, evidence in support of the neuroinvasive potential of SARS-CoV-2 has emerged. Considering that viral parkisonism was observed as a consequence of encephalopathies caused by viral infections, it has been already suggested that COVID-19 could affect the dopaminergic neurons and contribute to neurodegeneration in Parkinson's disease (PD), by promoting the formation of amyloid fibrils constituted by the PD-related protein α-synuclein. Here, we observe not only that SARS-CoV-2 viral spike protein and nucleocapsid protein can alone promote α-synuclein aggregation but also that the spike protein organization in a corona shape on the viral envelope may be crucial in triggering fast amyloid fibrils formation, thus possibly contributing to PD pathogenesis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
ACS chemical neuroscience - 15(2024), 2 vom: 17. Jan., Seite 215-221 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zilio, Gianluca [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
α-synuclein |
|---|
| Anmerkungen: |
Date Completed 18.01.2024 Date Revised 18.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1021/acschemneuro.3c00468 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36622266X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36622266X | ||
| 003 | DE-627 | ||
| 005 | 20240118232044.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231227s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1021/acschemneuro.3c00468 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1263.xml |
| 035 | |a (DE-627)NLM36622266X | ||
| 035 | |a (NLM)38131609 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zilio, Gianluca |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a SARS-CoV-2-Mimicking Pseudoviral Particles Accelerate α-Synuclein Aggregation In Vitro |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.01.2024 | ||
| 500 | |a Date Revised 18.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Since the SARS-CoV-2 virus started spreading worldwide, evidence pointed toward an impact of the infection on the nervous system. COVID-19 patients present neurological manifestations and have an increased risk of developing brain-related symptoms in the long term. In fact, evidence in support of the neuroinvasive potential of SARS-CoV-2 has emerged. Considering that viral parkisonism was observed as a consequence of encephalopathies caused by viral infections, it has been already suggested that COVID-19 could affect the dopaminergic neurons and contribute to neurodegeneration in Parkinson's disease (PD), by promoting the formation of amyloid fibrils constituted by the PD-related protein α-synuclein. Here, we observe not only that SARS-CoV-2 viral spike protein and nucleocapsid protein can alone promote α-synuclein aggregation but also that the spike protein organization in a corona shape on the viral envelope may be crucial in triggering fast amyloid fibrils formation, thus possibly contributing to PD pathogenesis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Parkinson’s disease | |
| 650 | 4 | |a aggregation | |
| 650 | 4 | |a coronavirus | |
| 650 | 4 | |a spike | |
| 650 | 4 | |a α-synuclein | |
| 650 | 7 | |a alpha-Synuclein |2 NLM | |
| 650 | 7 | |a Spike Glycoprotein, Coronavirus |2 NLM | |
| 650 | 7 | |a spike protein, SARS-CoV-2 |2 NLM | |
| 700 | 1 | |a Masato, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Sandre, Michele |e verfasserin |4 aut | |
| 700 | 1 | |a Caregnato, Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Moret, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Maciola, Agnieszka Katarzyna |e verfasserin |4 aut | |
| 700 | 1 | |a Antonini, Angelo |e verfasserin |4 aut | |
| 700 | 1 | |a Brucale, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Cendron, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Plotegher, Nicoletta |e verfasserin |4 aut | |
| 700 | 1 | |a Bubacco, Luigi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ACS chemical neuroscience |d 2010 |g 15(2024), 2 vom: 17. Jan., Seite 215-221 |w (DE-627)NLM19578832X |x 1948-7193 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2024 |g number:2 |g day:17 |g month:01 |g pages:215-221 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1021/acschemneuro.3c00468 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2024 |e 2 |b 17 |c 01 |h 215-221 | ||